Liver cancer, mostly hepatocellular carcinoma (HCC), is the second leading cause of cancer mortality globally. Most patients were diagnosed at an advanced stage, and systemic therapy is the standard of care. All the approved systemic therapies for HCC are molecular targeted therapies with anti-angiogenic effects targeting the vascular endothelial growth factor signaling pathway. Sorafenib and lenvatinib are the first-line treatment, and regorafenib, ramucirumab, and cabozantinib are second-line treatment options. Although anti-PD-1 antibodies, including nivolumab and pembrolizumab, demonstrated promising anti-tumor effects as monotherapy for advanced HCC in phase II clinical trials, both failed in phase III studies. Anti-angiogenic treatment remains the backbone of systemic therapy for HCC. In this review, we summarized the approved anti-angiogenic medicines and discussed the potential strategies to improve the efficacy of anti-angiogenic therapy, including combination therapy with other treatments, and discussed the approaches to overcome the drawbacks of anti-angiogenic therapies.
Keywords: Anti-angiogenic therapy; CR, complete response; Combinational therapy; HCC, hepatocellular carcinoma; Hepatocellular carcinoma; ICI, immune checkpoint inhibitor; Molecular targeted therapy; ORR, objective response rate; OS, overall survival; PD-1, program death-1; PD-L1, program death-1 ligand; PFS, progression-free survival; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; Systemic therapy; TACE, transcatheter chemoembolization; TKI, tyrosine kinase inhibitor.
© 2020 Chongqing Medical University. Production and hosting by Elsevier B.V.